Also known as Lys-Glu · KE dipeptide
Synthetic Lys-Glu dipeptide — the defined short-peptide successor to Thymalin, studied for immune and aging endpoints.
Vilon is a synthetic dipeptide (Lys-Glu) developed as a defined-sequence "Cytogen" successor to the thymic extract Thymalin. Russian research studied it as a tissue bioregulator of immune function and an aging-axis peptide.
Vilon is one of the simplest members of the Khavinson short-peptide bioregulator class — a two–amino-acid sequence (Lys-Glu) intended to reproduce, in a defined synthetic form, the immune-regulating activity attributed to the thymic extract Thymalin.
The class hypothesis is that such short peptides penetrate the cell and bind specific promoter regions of DNA, modulating transcription in a tissue-selective way. Reported studies examined effects on immune indices, chromatin activation, and lifespan in model organisms. As with the rest of the class, the literature is concentrated in one research tradition and lacks large independent trials; it is not FDA-approved.
Proposed direct gene-regulatory binding (short peptide–DNA interaction) modulating immune-related gene expression.
Behind every vial of Vilon is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Vilon, specifically, is brought into being.
On paper, Vilon weighs in at roughly 275.3 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Vilon means roughly 2 coupling cycles on the synthesizer — one protected residue added at a time, which is also 2 chances for an incomplete coupling to seed a deletion impurity. It is a short sequence, which makes the build comparatively tractable — but short does not mean trivial, and purity is still won or lost downstream.
The crude mixture — Vilon plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Vilon proves itself: identity confirmed by mass spectrometry against its ~275.3 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Vilon — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Vilon to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Vilon, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Vilon is a synthetic Lys-Glu dipeptide studied in Russia as a defined-sequence immune and aging bioregulator — the short-peptide successor to the thymic extract Thymalin.
The class hypothesis is that the short peptide enters the cell and binds specific DNA promoter regions, modulating gene expression in a tissue-selective way. This mechanism is proposed, not firmly established.
No — it is concentrated in a single research tradition and is largely preclinical, so findings are preliminary. This page is a research and educational reference.
The active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
ViewRecombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.